Atlas FDA

ExAblate

FDA premarket approval P150038/S006 · decided 2018-12-16

Approval details

PMA number
P150038
Supplement
S006
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
ExAblate
Generic name
MR-guided focused ultrasound system
Applicant
Insightec
Date received
2018-03-07
Decision date
2018-12-16
Days to decision
284 days
Decision code
APPR
Product code
POH
Advisory committee
Neurology
Expedited review
No
Location
Tirat Carmel
Statement
Approval for the Exablate Model 4000 (Neuro). The device is intended in the unilateral Thalamotomy (ventralis intermedius) treatment of Tremor-dominant Parkinson’s Disease with medication-refractory tremor. Patients must be at least age 30.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.